SuperGen Inc. has announced as part of a series of presentations at the 2008 AACR Annual Meeting that S-110, its DNA methyltransferase inhibitor, improves in vivo efficacy of decitabine (Abstract No. 2613).
Entitled, "Decitabine administered as a Dinucleotide prodrug increases its in vivo efficacy due to enhanced drug delivery and stability," the poster highlights data indicating that S-110 showed robust anti-tumor activity in prostate and cisplatin-resistant ovarian carcinoma xenograft models. Additionally, S-110 restored sensitivity to cisplatin in the ovarian cancer model. Importantly, reduced toxicity was observed along with an increased half-life compared to decitabine.
"S-110's increased half-life, reduced toxicity and improvement of efficacy when compared to decitabine in its currently marketed formulations make it an attractive, next-generation hypomethylator for the treatment of hematoligic malignancies," said Dr. James Manuso, SuperGen's President and CEO.
Dr. James added, "As we develop S-110 further, we will continue to explore its potential to enhance solid tumors' sensitivity to standard chemotherapy agents, including cisplatin. We look forward to advancing this promising candidate to clinical trials later this year or early next year."